Cargando…

Optimising the Nadroparin Dose for Thromboprophylaxis During Hemodialysis by Developing a Population Pharmacodynamic Model Using Anti-Xa Levels

INTRODUCTION: The optimal nadroparin dose in patients undergoing hemodialysis is difficult to determine in clinical practice. Anti-Xa levels ≥ 0.4 IU/mL and < 2.0 IU/mL are suggested to prevent thrombus formation within the extracorporeal circuit whilst minimizing bleeding risk. We aimed to chara...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jaspers, Tessa C. C., Meijer, Charlotte E., Vleming, Louis Jean, Franssen, Casper F. M., Diepstraten, Jeroen, Lukens, Michael V., van den Bemt, Patricia M. L. A., Maat, Barbara, Khorsand, Nakisa, Touw, Daniël J., Koomen, Jeroen V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652168/ https://www.ncbi.nlm.nih.gov/pubmed/36040615 http://dx.doi.org/10.1007/s40262-022-01162-x

Ejemplares similares

A meta‐analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor–related major bleeding
por: Jaspers, Tessa, et al.
Publicado: (2021)

The right time to measure anti-Xa activity in critical illness: pharmacokinetics of therapeutic dose nadroparin
por: Sytema, Jelmer G., et al.
Publicado: (2023)

Effect of nadroparin on anti-Xa activity during nocturnal hemodialysis
por: Buitenwerf, Edward, et al.
Publicado: (2015)

Trough anti-Xa activity after intermediate dose nadroparin for thrombosis prophylaxis in critically ill patients with COVID-19 and acute kidney injury
por: Eck, R. J., et al.
Publicado: (2022)

Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID‐19 intensive care unit patients
por: Romano, Lorenzo G. R., et al.
Publicado: (2022)

A multifaceted clinical decision support intervention to improve adherence to thromboprophylaxis guidelines
por: Jaspers, Tessa, et al.
Publicado: (2021)

Low and Highly Variable Exposure to Prophylactic LMWH Nadroparin in Critically Ill Patients: Back to the Drawing Board for Prophylactic Dosing?
por: Diepstraten, Jeroen, et al.
Publicado: (2022)

Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study
por: Barni, Sandro, et al.
Publicado: (2011)

The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis
por: Wei, Matthew Y., et al.
Publicado: (2015)

Therapeutically dosed low molecular weight heparins in renal impairment: a nationwide survey
por: Jaspers, Tessa Corrine Catherina, et al.
Publicado: (2022)

Bleeding complications of thromboprophylaxis with dabigatran, nadroparin or rivaroxaban for 6 weeks after total knee arthroplasty surgery: a randomised pilot study
por: van der Veen, Lucia, et al.
Publicado: (2021)

Anti-Xa Directed Thromboprophylaxis in Critically Ill Patients with Coronavirus Disease 2019
por: Mohamed, Adham, et al.
Publicado: (2022)

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
por: Persson, Pontus B
Publicado: (2015)

The effect of renal impairment and obesity on anti-Xa peak and trough levels in patients receiving therapeutic doses of nadroparin: a comparison with control patients
por: Mast, L., et al.
Publicado: (2023)

Tinzaparin vs. Nadroparin Safety and Efficacy in Neurosurgery
por: Wilhelmy, Florian, et al.
Publicado: (2021)

Comparison of Anti-factor Xa Levels in Female and Male Patients with Obesity After Enoxaparin Application for Thromboprophylaxis
por: Wagner, Jonas, et al.
Publicado: (2022)

Nadroparine calcium or enoxaparine in acute coronary syndrome patients suffering renal insufficiency: The nadroparin versus enoxaparin (NaVe) study design
por: Gurfinkel, Enrique P, et al.
Publicado: (2004)

Antifactor Xa Levels in Critically Ill Korean Patients Receiving Enoxaparin for Thromboprophylaxis: A Prospective Observational Study
por: Lim, So Yeon, et al.
Publicado: (2013)

Nadroparin calcium: Spontaneous retroperitoneal bleeding: 2 case reports
Publicado: (2022)

Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19
por: Hamilton, David Oliver, et al.
Publicado: (2021)

Antitumor effects of nadroparin combined with radiotherapy in Lewis lung cancer models
por: Zhuang, Xibing, et al.
Publicado: (2018)

Effectiveness and Safety of Nadroparin Therapy in Preterm and Term Neonates with Venous Thromboembolism
por: Sol, Jeanine, et al.
Publicado: (2021)

Anti-factor Xa Activity Is Not Associated With Venous Thromboembolism in Critically Ill Patients Receiving Enoxaparin for Thromboprophylaxis: A Retrospective Observational Study
por: Dibiasi, Christoph, et al.
Publicado: (2022)

Rare complication of nadroparin injections: Skin necrosis and heparin‐induced thrombocytopenia syndrome
por: Malinauskiene, Laura, et al.
Publicado: (2022)

Sequential Therapy of Nadroparin and Rivaroxaban in the Initial Treatment of Patients With Acute Pulmonary Embolism
por: Xiong, Wei, et al.
Publicado: (2022)

Fixed Versus Variable Dosing of Prothrombin Complex Concentrate in Vitamin K Antagonist-Related Intracranial Hemorrhage: A Retrospective Analysis
por: Abdoellakhan, Rahat Amadkhan, et al.
Publicado: (2016)

Nadroparine-induced skin necrosis on a patient with essential thrombocythaemia: a case report
por: Pramateftakis, Manousos-Georgios, et al.
Publicado: (2009)

Fondaparınux Versus Nadroparın for Preventıon of Venous Thromboembolısm After Electıve Hıp and Knee Arthroplasty()
por: Argun, Mahmut, et al.
Publicado: (2013)

Preemptive dosage reduction of nadroparin in patients with renal failure: a retrospective case series
por: Russcher, Marije, et al.
Publicado: (2013)

Population Pharmacokinetics and Probability of Target Attainment Analysis of Nadroparin in Different Stages of COVID-19
por: Piwowarczyk, Paweł, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa
por: Parasrampuria, Dolly A., et al.
Publicado: (2015)

Anti-Xa activity after subcutaneous administration of dalteparin in intensive care unit patients with and without subcutaneous oedema
por: Rommers, M, et al.
Publicado: (2005)

Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in management of major bleeding
por: Abdoellakhan, Rahat A., et al.
Publicado: (2019)

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
por: Frost, Charles, et al.
Publicado: (2013)

Localized and Generalized Skin Adverse Drug Reactions to Nadroparin Calcium Injection in 6 Cases of Pregnant Women
por: Chen, Ting, et al.
Publicado: (2022)

Effects of Routine Antithrombotic-Adjusted Dose of Rivaroxaban and Nadroparin Calcium on Tendon Healing of Rats: An Experimental Study
por: Altun, Suleyman, et al.
Publicado: (2021)

An XA21-Associated Kinase (OsSERK2) Regulates Immunity Mediated by the XA21 and XA3 Immune Receptors
por: Chen, Xuewei, et al.
Publicado: (2014)

Aspirin thromboprophylaxis in joint replacement surgery
por: Sharda, Anish V., et al.
Publicado: (2022)

Xa tantlin lisantiago /
por: Ibarra, José Xochihua
Publicado: (1993)

Coagulation Factor Xa
por: Brown, Mark A., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_fc5inig5safrmuocg7okkiimpu